New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- A latest research report [115+] pages with 360-degree visibility, titled “Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry ...

Vera Therapeutics, Inc. (NASDAQ:VERA) saw its stock soar by 80% following the announcement of encouraging data from its ...

These promising alternatives include: For people with immunodeficiencies, subcutaneous immunoglobulin (SCIg) may be a suitable alternative. This involves injecting purified immunoglobulin into the ...

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP).

This medication may rarely cause serious problems from blood clots (such as heart attack, stroke, blood clots in the lungs or legs). You may be at increased risk for blood clots if you are an ...

Decades into its tenure as a drug seller, CSL Behring has finally dipped its toe into the waters of TV advertising. | Decades ...

"Moving to IVIG before the infections start makes much more sense." Banerjee also commented that, in general, "the myeloma field has been moving from IV treatments to subcutaneous treatments to ...

“The availability of the 10g prefilled syringe is CSL Behring’s latest development in helping the rare disease community effectively manage PI and CIDP, as some patients may require treatment ...

(Bloomberg) -- Australian biotech group CSL Ltd. has begun enrolling US patients in a late-stage study to test a self-administered antibody-based therapy for a blood circulation issue that’s one ...

Finally, subcutaneous immunoglobulin (SCIG), an immunoglobulin treatment administered under the skin, is an alternative treatment you could consider. SCIG can be administered at home and uses a ...

HYQVIA is the first and only facilitated subcutaneous immunoglobulin (fSCIG) for CIDP, approved earlier this year by the U.S. Food and Drug Association (FDA) as maintenance therapy in adults with ...